Latest Period
Q1 2026
Security Snapshot
AVADEL PHARMACEUTICALS PLC - Ordinary Shares, nominal value $0.01 per share (AVDL) Institutional Ownership
CUSIP: G29687103
13F Institutional Holders and Ownership History from Q1 2023 to Q2 2026
Institutions Reporting
1
Shares (Excl. Options)
20
Price
$21.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, nominal value $0.01 per share
- Symbol
- AVDL
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 20
- Total 13F value
- $426
- Share change
- -66,933,366
- Value change
- -$1,442,156,498
- Number of holders
- 1
- Shares outstanding
- 95,992,895
- SEC-reported price per share
- $21.69
- Insider filing price
- $21.69
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AVDL - AVADEL PHARMACEUTICALS PLC - Ordinary Shares, nominal value $0.01 per share is tracked under CUSIP G29687103.
- 1 institution reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $426 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q1 2026.
Security key
G29687103
Latest holder period
Q1 2026
13F holders
1
13D/G owners
4
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G29687103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
AVDL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7% | $59,674,993 | 6,742,480 | BlackRock, Inc. | 30 Jun 2025 | |||
| VANGUARD GROUP INC | 5.7% | $49,243,692 | 5,564,259 | The Vanguard Group | 30 Jun 2025 | |||
| JANUS HENDERSON GROUP PLC | 1.9% | -72% | $39,176,620 | -$120,413,722 | 1,823,865 | -75% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| BRANDES INVESTMENT PARTNERS, LP | 0.2% | -95% | $4,700,576 | -$117,105,674 | 218,835 | -96% | BRANDES INVESTMENT PARTNERS, LP | 31 Dec 2025 |
As of 31 Mar 2026, 1 institutional investors reported holding 20 shares of AVADEL PHARMACEUTICALS PLC - Ordinary Shares, nominal value $0.01 per share (AVDL). This represents 0% of the company’s total 95,992,895 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q1 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 0 | $0 | -$426 | $21.69 | 0 |
| 2026 Q1 | 20 | $426 | -$1,442,156,498 | $21.30 | 1 |
| 2025 Q4 | 73,576,940 | $1,585,325,518 | -$27,117,037 | $21.55 | 207 |
| 2025 Q3 | 79,038,211 | $1,206,765,098 | -$19,096,496 | $15.27 | 183 |
| 2025 Q2 | 80,502,710 | $712,425,370 | +$33,247,786 | $8.85 | 166 |
| 2025 Q1 | 77,015,539 | $605,345,850 | -$36,026,238 | $7.83 | 169 |
| 2024 Q4 | 78,709,574 | $827,347,590 | +$46,727,000 | $10.51 | 153 |
| 2024 Q3 | 73,371,084 | $962,302,695 | +$83,134,728 | $13.12 | 169 |
| 2024 Q2 | 66,234,240 | $931,472,460 | +$905,737,723 | $14.06 | 142 |
| 2024 Q1 | 1,624,846 | $27,443,649 | +$27,443,649 | $16.89 | 7 |
| 2023 Q2 | 0 | $0 | -$4,287 | $21.69 | 0 |
| 2023 Q1 | 468 | $4,287 | +$4,287 | $9.16 | 1 |